Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > Lumera Corporation and Plexera Bioscience Announce Speakers at Three Conferences

Lumera Corporation (NASDAQ:LMRA), a leader in the field of photonic communications, announced today that Dr. Raluca Dinu, Vice President - Electro-Optic Business Unit, will speak at the Global Crown Capital Nanotechnology conference on November 7 in Palo Alto, CA. She is also scheduled to speak at the 30th Annual Paulson Investment Westergaard conference in New York on November 13. In both cases, Dinu will give an overview of Lumera Corporation's electro-optic capabilities and products.

Lumera Corporation and Plexera Bioscience Announce Speakers at Three Conferences

BOTHELL, WA | Posted on October 24th, 2007

Plexera Bioscience LLC, a wholly owned subsidiary of Lumera, announced that Dr. Joe Vallner, Chairman and CEO of Plexera, will be a speaker at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare conference in New York on November 5. Plexera also announced that Dr. Timothy Londergan, President and COO, will give an overview of Plexera at the 30th Annual Westergaard conference in New York on November 13.

Additional information on the Global Crown conference can be obtained at ; on the Acumen Biofin conference at ; and on the Westergaard conference at .


About Lumera Corporation
Lumera is a leader in the field of photonic communications. The company designs electro-optic components based on proprietary polymer compounds for the communications/computing industries.

About Plexera Bioscience LLC

Plexera Bioscience LLC was established in July of 2007 as a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA) and is focused on providing the life sciences market with tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

For more information, please click here

Lumera Corporation
(Investor Relations)
Hélène F. Jaillet, Ph.D, 425-398-6546
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Scientists design a QKD-based quantum private query with no failure November 25th, 2015

MIT mathematicians identify limits to heat flow at the nanoscale: New formula identifies limits to nanoscale heat transfer, may help optimize devices that convert heat to electricity November 25th, 2015

Physicists explain the unusual behavior of strongly disordered superconductors: Using a theory they developed previously, the scientists have linked superconducting carrier density with the quantum properties of a substance November 25th, 2015

Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015


Nanometrics Announces Upcoming Investor Events November 18th, 2015

FEI and ICON Analytical Demonstrate the Power of TEM for Materials and Life Sciences Research: FEI’s Talos scanning transmission electron microscope will be available for demos and workshops at the Indian Institute of Science from 23 November to 15 December 2015 November 17th, 2015

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees November 15th, 2015

Breakthrough in superconducting materials opens new path to fusion: New high-temperature superconducting materials are also compatible with high magnetic fields November 13th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic